ArticleFrontiers in cell and developmental biology2026
Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isorhamnetin (ISO), a natural flavonoid derived from traditional Chinese medicine, has demonstrated potential antitumor activity. This study aimed to investigate the effects of ISO on the proliferation, migration, and apoptosis of mouse breast cancer 4T1 cells and to explore the underlying mechanisms. Methods: Cell viability was evaluated using a Cell Counting Kit-8 (CCK-8) assay. Wound healing and colony formation assays were performed to assess migration and clonogenic ability. Intracellular reactive oxygen species (ROS) levels and mitochondrial membrane potential were measured to evaluate oxidative stress and mitochondrial function. Quantitative polymerase chain reaction and Western blot analyses were conducted to determine the expression of the TIGIT/CD155 signaling axis. Results: ISO inhibited 4T1 cell proliferation in a concentration- and time-dependent manner. It significantly reduced migration and clonogenic capacity. ISO treatment increased intracellular ROS levels and disrupted mitochondrial membrane potential, indicating oxidative stress-mediated mitochondrial dysfunction. Additionally, ISO markedly downregulated the mRNA and protein expression levels of the TIGIT/CD155 signaling axis (p < 0.01). Conclusion: ISO suppresses proliferation and migration and induces apoptosis in 4T1 breast cancer cells, potentially through modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 signaling axis. These findings provide mechanistic insight into the antitumor effects of ISO and support its potential as a therapeutic candidate for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.